Concepts for the Integration and Implementation of mHealth Apps for Patients With Mental Disorders: Scoping Review.

Background: Mental and behavioral disorders affect approximately 28% of the adult population in Germany per year, with treatment being provided through a diverse health care system. Yet there are access and capacity problems in outpatient mental health care. One innovation that could help reduce these barriers and improve the current state of care is the use of mobile health (mHealth) apps, known in Germany as Digitale Gesundheitsanwendungen (DiGA).

Charting recovery pathways in Sweden: The role of time, gender and meaningful activities.

To explore the influence of gender and time in addiction recovery on engagement in meaningful activities and the reduction of harmful behaviours among the recovery population in Sweden. Participants were recruited through social media, recovery and treatment services, and snowballing, resulting in a sample of 110 individuals who consider themselves in addiction recovery for more than 3 months. Bivariate analyses were used to explore gender differences in relation to personal characteristics and current utilization of recovery support.

Rare variants in in patients with chronic thromboembolic pulmonary hypertension.

Background: The pathogenesis of chronic thromboembolic pulmonary hypertension (CTEPH) is poorly understood. Studies of the genetic risk factors for CTEPH are likely to improve our understanding of CTEPH pathogenesis and may lead to novel treatment and prevention strategies. Genetic analysis focused on shared gene variants in high-risk disease pedigrees can aid in the identification of rare variants with a strong effect on disease risk.

Legacy hERG study data in contemporary integrated risk assessments - mitigating the risk of protocol and positive control article differences.

Testing new molecules against the hERG potassium channel has been a routine component of secondary pharmacology assessments for more than a quarter of a century. In 2005, the ICH S7B guidance required a GLP hERG study prior to first administration of new chemical entities to man. In 2022, the ICH S7B Q&As introduced some 'best practice' recommendations for the hERG assessment.